VistaGen Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by VistaGen Therapeutics, Inc. on April 26, 2021. The report details a corporate event regarding the conversion of preferred stock into common stock.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The only financial figure disclosed relates to the historical gross proceeds of $100 million from the underwritten public offering of Series D Convertible Preferred Stock completed in December 2020.
Material Changes
- Stock Conversion: As of April 26, 2021, all previously issued shares of Series D Convertible Preferred Stock were converted into 46.0 million shares of Common Stock.
- Share Count Update: Following the conversion, the total number of Common Stock shares issued and outstanding increased to 190,202,496.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, contingencies, or discussion of unusual items beyond the stock conversion event.
Investor Verification Checklist
- Verify the total outstanding share count of 190,202,496 in subsequent filings.
- Confirm the dilution impact of the 46.0 million newly issued shares on existing shareholders.
- Review the terms of the Series D Preferred Stock conversion to ensure no remaining obligations exist.